SCHEMBL8315420

SCHEMBL8315420

Oc1ccc(C2CCNCC2)c(O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
QDPR P09417 1/20 0.50
CHRNB2 P17787 1/20 0.46
CHRNA4 P43681 1/20 0.46
HTR2C P28335 6/20 0.44
USP7 Q93009 4/20 0.43
IKBKB O14920 1/20 0.41
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
GAA P10253 1/20 0.40
CYP2D6 P10635 1/20 0.40
MAPT P10636 1/20 0.40
THRB P10828 1/20 0.40
CYP2C9 P11712 1/20 0.40
HPGD P15428 1/20 0.40
ALOX12 P18054 1/20 0.40
CYP2C19 P33261 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1979199 0.98 QDPR (0.49) QDPRCHRNB2CHRNA4HTR2CUSP7
SCHEMBL19249421 0.86 TYR (0.48) CHRNB2CHRNA4MEN1ALDH1A1CYP1A2
SCHEMBL8313932 0.85 QDPR (0.55) QDPRCHRNB2CHRNA4HTR2CUSP7
Butylamine SCHEMBL28820128 0.84 IKBKB (0.40) QDPRHTR2CIKBKBMEN1CYP3A4
SCHEMBL3162433 0.82 ALDH1A1 (0.43) CHRNB2CHRNA4MEN1ALDH1A1CYP1A2
SCHEMBL29871375 0.82 ALDH1A1 (0.43) CHRNB2CHRNA4MEN1ALDH1A1CYP1A2
SCHEMBL24310183 0.81 USP7 (0.52) QDPRCHRNB2CHRNA4HTR2CUSP7
SCHEMBL12737660 0.81 SLC6A2 (0.49) QDPRCHRNB2CHRNA4HTR2CALDH1A1
SCHEMBL12656346 0.81 SLC6A2 (0.52) QDPRCHRNB2CHRNA4
SCHEMBL19347098 0.81 HTR2C (0.58) QDPRCHRNB2CHRNA4HTR2CUSP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9650337-B2 Method of synthesising 4-piperidin-4-yl-benzene-1,3-diol and the salts of same and novel compound tert-butyl 4-(2,4-dihydroxy-phenyl)-4-hydroxy-piperidine-1-carboxylate GALDERMA RESEARCH & DEVELOPMENT (FR) 2017-05-16 US claimed
EP-2956438-B1 METHOD FOR SYNTHESISING 4-PIPERIDIN-4-YL-BENZENE-1,3-DIOL AND THE SALTS OF SAME AND COMPOUND TERT-BUTYL 4-(2,4-DIHYDROXY-PHENYL)-4-HYDROXY-PIPERIDINE-1-CARBOXYLATE GALDERMA RES & DEV (FR) 2017-03-22 EP claimed
US-20150376126-A1 METHOD FOR THE SYNTHESISING 4-PIPERIDIN-4-YL-BENZENE-1,3-DIOL AND THE SALTS OF SAME AND NOVEL COMPOUND TERT-BUTYL 4-(2,4-DIHYDROXY-PHENYL)-4-HYDROXY-PIPERIDINE-1-CARBOXYLATE GALDERMA RESEARCH & DEVELOPMENT (FR) 2015-12-31 US claimed
EP-2956438-A2 METHOD FOR SYNTHESISING 4-PIPERIDIN-4-YL-BENZENE-1,3-DIOL AND THE SALTS OF SAME AND NOVEL COMPOUND TERT-BUTYL 4-(2,4-DIHYDROXY-PHENYL)-4-HYDROXY-PIPERIDINE-1-CARBOXYLATE Galderma Research & Development (FR) 2015-12-23 EP claimed
WO-2014125233-A2 METHOD FOR SYNTHESISING 4-PIPERIDIN-4-YL-BENZENE-1,3-DIOL AND THE SALTS OF SAME AND NOVEL COMPOUND TERT-BUTYL 4-(2,4-DIHYDROXY-PHENYL)-4-HYDROXY-PIPERIDINE-1-CARBOXYLATE GALDERMA RESEARCH & DEVELOPMENT (FR) 2014-08-21 WO claimed
EP-0630887-B1 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists ZENECA LTD (GB) 1999-07-28 EP claimed
US-5654299-A TREATING RESPIRATORY SYSTEM DISORDER (I.E. ASTHMA) WITH NEUROKININ 2 RECEPTOR ANTAGONIST ZENECA LIMITED (GB) 1997-08-05 US claimed
EP-0630887-A1 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists ZENECA LIMITED (GB) 1994-12-28 EP claimed
JP-59029662-A None JP disclosed
JP-59029662-A None JP disclosed
JP-59029663-A None JP disclosed
US-9650337-B2 Method of synthesising 4-piperidin-4-yl-benzene-1,3-diol and the salts of same and novel compound tert-butyl 4-(2,4-dihydroxy-phenyl)-4-hydroxy-piperidine-1-carboxylate GALDERMA RESEARCH & DEVELOPMENT (FR) 2017-05-16 US disclosed
US-9650337-B2 Method of synthesising 4-piperidin-4-yl-benzene-1,3-diol and the salts of same and novel compound tert-butyl 4-(2,4-dihydroxy-phenyl)-4-hydroxy-piperidine-1-carboxylate GALDERMA RESEARCH & DEVELOPMENT (FR) 2017-05-16 US disclosed
US-9650337-B2 Method of synthesising 4-piperidin-4-yl-benzene-1,3-diol and the salts of same and novel compound tert-butyl 4-(2,4-dihydroxy-phenyl)-4-hydroxy-piperidine-1-carboxylate GALDERMA RESEARCH & DEVELOPMENT (FR) 2017-05-16 US disclosed
EP-0630887-B1 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists ZENECA LTD (GB) 1999-07-28 EP disclosed
US-5654299-A TREATING RESPIRATORY SYSTEM DISORDER (I.E. ASTHMA) WITH NEUROKININ 2 RECEPTOR ANTAGONIST ZENECA LIMITED (GB) 1997-08-05 US disclosed
EP-0630887-A1 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists ZENECA LIMITED (GB) 1994-12-28 EP disclosed
JP-S5929662-A 4-(2,4-DIHYDROXYPHENYL)PIPERIDINE COMPOUND AND ITS PREPARATION MITSUI PETROCHEM IND LTD 1984-02-16 JP disclosed
JP-S5929662-A 4-(2,4-DIHYDROXYPHENYL)PIPERIDINE COMPOUND AND ITS PREPARATION MITSUI PETROCHEM IND LTD 1984-02-16 JP disclosed
JP-S5929663-A 4-(2,4-DIHYDROXYPHENYL)-3,4-DEHYDROPIPERIDINE COMPOUND AND ITS PREPARATION MITSUI PETROCHEM IND LTD 1984-02-16 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376126-A1 METHOD FOR THE SYNTHESISING 4-PIPERIDIN-4-YL-BENZENE-1,3-DIOL AND THE SALTS OF SAME AND NOVEL COMPOUND TERT-BUTYL 4-(2,4-DIHYDROXY-PHENYL)-4-HYDROXY-PIPERIDINE-1-CARBOXYLATE HPD, CYP4B1, PAH QDPR 28/4885CHRNB2 4287/4885CHRNA4 3651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.